Biological
ETBX-051 clinical trials
Also written ETBX-051.
- studies test it
- 16
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
- ETBX-051
- 16
Studies by the year they started
16 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2017 | 6 |
| 2018 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (16) · ETBX-061 (16) · GI-6301 (16) · Avelumab (16) · Cyclophosphamide (15) · Fluorouracil (15) · Leucovorin (14) · Paclitaxel (14)
Studies
Open first, then newest update. How each study uses ETBX-051 is read from its arms, and is right about nine times in ten.
Testing it · 16
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as ETBX-051
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as ETBX-051
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as ETBX-051
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as ETBX-051
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnPhase 1/2ImmunityBio, Inc.NCT03647423Written as ETBX-051
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167164Written as ETBX-051
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as ETBX-051
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as ETBX-051
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as ETBX-051
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as ETBX-051
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as ETBX-051
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as ETBX-051
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as ETBX-051
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as ETBX-051
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as ETBX-051
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as ETBX-051
Given in every arm · 3 — ETBX-051 is usual care beside what is tested
- QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03563157Written as ETBX-051
- Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesCompletedPhase 1National Cancer Institute (NCI)NCT03481816Written as ETBX-051; adenoviral brachyury vaccine
- Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerCompletedPhase 1National Cancer Institute (NCI)NCT03384316Written as ETBX-051; adenoviral brachyury vaccine
Codes
What other systems call ETBX-051 · ClinicalTrials.gg INT016126
- UNII (FDA) BPG11IF0HWETBX-051One source FDA
- NCI Thesaurus C143034Adenoviral Brachyury Vaccine ETBX-051One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BPG11IF0HW | ETBX-051 | One source FDA |
| NCI Thesaurus | C143034 | Adenoviral Brachyury Vaccine ETBX-051 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.